<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Data on 65 sibling bone marrow transplantations (BMT) for various <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> are reported </plain></SENT>
<SENT sid="1" pm="."><plain>51 patients had <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 8 severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, 4 <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, one suffered from non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and one from <z:mpath ids='MPATH_173'>myeloid metaplasia</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> but two patients have engrafted </plain></SENT>
<SENT sid="3" pm="."><plain>Overall, 43 (66%) of 65 patients were alive 0,03-7,2 years (median not reached) as of June 23, 1997 </plain></SENT>
<SENT sid="4" pm="."><plain>Median time of observation was 13 months </plain></SENT>
<SENT sid="5" pm="."><plain>Outcome of standard risk patients was significantly better than that of high risk patients (p=0,006) </plain></SENT>
<SENT sid="6" pm="."><plain>Our data confirm, that sibling BMT is an effective treatment modality with acceptable toxicity for younger patients with an early stage of serious <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> </plain></SENT>
</text></document>